Tags

Type your tag names separated by a space and hit enter

Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients.
J Dermatolog Treat. 2020 Jul 07 [Online ahead of print]JD

Abstract

BACKGROUND

Little data are available concerning the outcome of rituximab (RTX) therapy in pediatric patients with autoimmune bullous diseases (AIBDs).

OBJECTIVE

We sought to evaluate safety and efficacy of RTX administration in pediatric patients with AIBDs and to assess first-line RTX therapy in pemphigus patients.

METHODS

AIBD patients consisting of 12 pemphigus patients and a patient with bullous pemphigoid who received RTX before the age of 18 were enrolled. Detailed information regarding patients' outcome after the first RTX cycle was assessed.

RESULTS

The mean age of the patients at RTX infusion was 15 ± 2 years. Six patients in the pemphigus group received RTX as first-line therapy. In pemphigus patients: complete remission (on minimal therapy) was achieved by seven patients, partial remission (on minimal therapy) and complete remission (off therapy) were achieved by three patients and one, respectively. Relapse occurred in nine patients, which were mostly mild. Likewise, the BP patient received RTX with a good clinical response. The observed adverse events were mostly mild infusion reactions and a case of sepsis.

CONCLUSION

Rituximab is safe and effective in childhood/juvenile patients with AIBDs. Furthermore, RTX can be used as first-line treatment in pediatric patients with pemphigus.

Authors+Show Affiliations

Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32589481

Citation

Kianfar, Nika, et al. "Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases as First-line and Second-line Treatment: a Case Series of 13 Patients." The Journal of Dermatological Treatment, 2020, pp. 1-6.
Kianfar N, Dasdar S, Mahmoudi H, et al. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients. J Dermatolog Treat. 2020.
Kianfar, N., Dasdar, S., Mahmoudi, H., Tavakolpour, S., Balighi, K., & Daneshpazhooh, M. (2020). Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients. The Journal of Dermatological Treatment, 1-6. https://doi.org/10.1080/09546634.2020.1788702
Kianfar N, et al. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases as First-line and Second-line Treatment: a Case Series of 13 Patients. J Dermatolog Treat. 2020 Jul 7;1-6. PubMed PMID: 32589481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients. AU - Kianfar,Nika, AU - Dasdar,Shayan, AU - Mahmoudi,Hamidreza, AU - Tavakolpour,Soheil, AU - Balighi,Kamran, AU - Daneshpazhooh,Maryam, Y1 - 2020/07/07/ PY - 2020/6/27/pubmed PY - 2020/6/27/medline PY - 2020/6/27/entrez KW - Rituximab KW - autoimmune bullous disease KW - pediatric KW - pemphigus SP - 1 EP - 6 JF - The Journal of dermatological treatment JO - J Dermatolog Treat N2 - BACKGROUND: Little data are available concerning the outcome of rituximab (RTX) therapy in pediatric patients with autoimmune bullous diseases (AIBDs). OBJECTIVE: We sought to evaluate safety and efficacy of RTX administration in pediatric patients with AIBDs and to assess first-line RTX therapy in pemphigus patients. METHODS: AIBD patients consisting of 12 pemphigus patients and a patient with bullous pemphigoid who received RTX before the age of 18 were enrolled. Detailed information regarding patients' outcome after the first RTX cycle was assessed. RESULTS: The mean age of the patients at RTX infusion was 15 ± 2 years. Six patients in the pemphigus group received RTX as first-line therapy. In pemphigus patients: complete remission (on minimal therapy) was achieved by seven patients, partial remission (on minimal therapy) and complete remission (off therapy) were achieved by three patients and one, respectively. Relapse occurred in nine patients, which were mostly mild. Likewise, the BP patient received RTX with a good clinical response. The observed adverse events were mostly mild infusion reactions and a case of sepsis. CONCLUSION: Rituximab is safe and effective in childhood/juvenile patients with AIBDs. Furthermore, RTX can be used as first-line treatment in pediatric patients with pemphigus. SN - 1471-1753 UR - https://www.unboundmedicine.com/medline/citation/32589481/Rituximab_in_childhood_and_juvenile_autoimmune_bullous_diseases_as_first_line_and_second_line_treatment:_a_case_series_of_13_patients_ L2 - https://www.tandfonline.com/doi/full/10.1080/09546634.2020.1788702 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.